Abivax S.A.
- Country
- 🇫🇷France
- Ownership
- -
- Employees
- 61
- Market Cap
- $752.4M
- Introduction
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- Conditions
- Moderately to Severely Active Crohn Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 212
- Registration Number
- NCT06456593
- Locations
- 🇺🇸
IMC Gulf Coast Gastroenterology, PC, Fairhope, Alabama, United States
🇺🇸Scottsdale Gastroenterology Specialists, Scottsdale, Arizona, United States
🇺🇸GI Alliance -Gurnee, Sun City, Arizona, United States
ABTECT - Maintenance
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 1050
- Registration Number
- NCT05535946
- Locations
- 🇺🇸
University of Alabama -Birmingham, Birmingham, Alabama, United States
🇺🇸Digestive Health Specialists of the Southeast, Dothan, Alabama, United States
🇺🇸Lakeview Clinical Research, Guntersville, Alabama, United States
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
- First Posted Date
- 2022-08-18
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 612
- Registration Number
- NCT05507216
- Locations
- 🇺🇸
University of Alabama -Birmingham, Birmingham, Alabama, United States
🇺🇸Research Solutions of Arizona, PC, Litchfield Park, Arizona, United States
🇺🇸Valleywise Health Medical Center, Phoenix, Arizona, United States
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
- First Posted Date
- 2022-08-18
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 612
- Registration Number
- NCT05507203
- Locations
- 🇺🇸
Digestive Health Specialists of the Southeast, Dothan, Alabama, United States
🇺🇸Lakeview Clinical Research, Guntersville, Alabama, United States
🇺🇸GI Alliance, Gurnee, Illinois, United States
Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 203
- Registration Number
- NCT05177835
- Locations
- 🇧🇪
UZ Leuven, Leuven, Belgium
🇨🇿Fakultni nemocnice u sv. Anny v Brne, Brno, Czechia
🇨🇿Nemocnice Slany, Slany, Czechia
Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464
- First Posted Date
- 2021-11-16
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 59
- Registration Number
- NCT05121714
- Locations
- 🇬🇧
Simbec-Orion, Merthyr Tydfil, United Kingdom
Safety and Pharmacokinetics Study in Healthy Japanese Volunteers
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 48
- Registration Number
- NCT05032560
- Locations
- 🇯🇵
Medical Corporation Heishinkai OPHAC Hospital, Osaka-shi, Osaka, Japan
ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 509
- Registration Number
- NCT04393038
- Locations
- 🇧🇪
Centre hospitalier Saint Pierre, Brussels, Belgium
🇧🇪Hôpital Erasme, Brussels, Belgium
🇧🇪UZ Gent, Gent, Belgium
Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 40
- Registration Number
- NCT04049448
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
🇧🇪UZ Gent, Gent, Belgium
🇧🇪UZ Leuven, Leuven, Belgium
Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 217
- Registration Number
- NCT04023396
- Locations
- 🇦🇹
Medizinische Universität Innsbruck, Innsbruck, Austria
🇦🇹Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria
🇦🇹Ordensklinikum Linz GmbH - Barmherzige Schwestern, Linz, Austria